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Introduction
Cancer of the lip and oral cavity is a rising problem worldwide 
with around 300,000 new cases per annum [1]. Squamous cell 
carcinoma (SCC) is detected in most patients with oral cancer 
[2]. Oral squamous cell carcinoma (OSCC) often happens at 
the gingiva and tongue and contributes above 90% of all oral 
cancers [3,4]. Genetic aspects and environmental factors, 
including alcohol abuse, smoking, viral infection, and chronic 
inflammation, have been associated with the pathogenesis of 
OSCC [5,6]. Due to the close anatomical structure of the oral 
mucosa and jaws, OSCC cells may frequently invade bone tis-
sues. Tumors derived from the floor of the mouth, the retro-
molar zone, and the tongue invade the mandible in 62%, 48%, 
and 42%, respectively [7]. The patients with oral cancer gen-
erally have severe dysfunctions of speaking, chewing, and/or 
swallowing. Treatment and rehabilitation are particularly difficult 
in the patients with bone invasion. Thus, early detection and 
accurate prediction of bone invasion is important to plan surgi-
cal ablation and minimize the spread of tumor cells, especially 
to induce maxillary or mandibular conservative surgery. 
In general, OSCC bone invasion shows histologically two dis-
tinct patterns. One is the less aggressive erosive pattern with 
a tumor mass that invades on a broad pushing front and is de-
tached from the bone by the connective tissue layer. The other 
is the invasive pattern in which the connective tissue layer is 
destroyed and the islands of tumor penetrate the bone [7-9] 
(Fig. 1). The formation of two patterns is affected by regional 
anatomic aspects of exposed bone, particularly whether the 
progressing front of the neoplasm contacts cancellous bone, by 
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the inherent properties of the malignant cells, and by the prop-
erties of tumor stroma and unidentified factors [10]. In spite 
of developments in OSCC treatment, recurrence and mortality 
rates are continuously increasing in patients with bone invasion 
[11].
To promote the quality of life and survival, it is necessary to 
improve diagnosis and therapy for OSCC patients with bone 
invasion based on molecular mechanisms by which OSCC 
invades bone. Therefore, we will focus on critical molecular 
markers associated with bone invasion by OSCC.
Proteases
Bone tissue consists of several distinct cell types and a 
mostly mineralized bone matrix. Osteocytes are integrated 
within bone and participate in the bone remodeling process 
with various cell types, including osteoprogenitor cells, os-
teoclasts, osteoblasts, marrow fibroblasts, and undifferenti-
ated cells [12,13]. Bone-tropic tumor cells produce a variety 
of enzymes to directly destroy extracellular matrix (ECM) and 
then migrate into the surrounding tissues [14]. In addition, 
tumor-derived proteolytic enzymes stimulate differentiation 
and maturation of bone cells, especially osteoclast precursors, 
resulting in osteolysis. Matrix metalloproteinases (MMPs) and 
cathepsins have been considered pivotal proteases in OSCC-
mediated bone invasion.
MMPs are the proteolytic enzymes responsible for degrada-
tion of fibrillar and non-fibrillar collagens, gelatin, elastin, and 
proteoglycans. Some MMPs are detected at high levels in 
cartilage and bone of mammals, including humans and mice, 
and are able to cleave native, non-denatured collagens by po-
tentially functioning as collagenases in vivo [15]. MMP-1 and 
MMP-9 were strongly expressed in highly differentiated BHY 
OSCC cells [16]. In another study, 9 of the 24 buccal SCC with 
mandibular invasion were intensely stained for active MMP-
7 but not 15 without bone invasion, representing that MMP-7 
is connected with mandibular invasion [17]. MMP-7 secreted 
from breast and prostate cancer cells cleaved the receptor ac-
tivator of nuclear factor-κB (RANK) ligand (RANKL) to its active 
soluble form, which triggers osteoclast differentiation and bone 
resorption [18,19]. In addition, high expression of MMP-9 is 
detected in the cytoplasm of invading OSCC cells [20]. 
Cathepsins are lysosomal proteases that degrade proteins at 
acidic pH. In normal cells, cathepsins modulate the immune 
responses and signaling pathways. Abnormal cathepsin activity 
is commonly implicated for altered immunologic and physio-
logical behavior that is caused by cancers [21,22]. Cathepsins, 
including cathepsin D, E, K, and L, play a crucial role in bone 
resorption by osteoclasts [23]. Procathepsin L was secreted 
from BHY cells in large amounts and the active cathepsin L 
degraded the demineralized bone matrix [24]. The injected 
BHY cells on the masseter muscle of nude mice developed 
into highly differentiated SCC invading the mandible, demon-
strating that cathepsin L might support to degrade the bone 
matrix [24]. Cathepsin B and D were intensely expressed in all 
78 SCC of tongue, gingiva, or floor of mouth and the labeling 
indices of the two cathepsins were closely correlated with the 
degree of bone invasion [25]. Furthermore, the survival period 
in patients with high serum levels of cathepsin B and D was 
short, indicating that these molecules could be useful as prog-
nostic indicators.
Cytokines
Osteoclasts are actually hematopoietic cells, originated from 
the macrophage/monocyte lineage. The differentiated osteo-
clasts attach to the bone matrix and then secrete protons to 
resorb inorganic components and soluble enzymes to degrade 
organic components of bone matrix [26]. Two hematopoietic 





Fig. 1. Distinct patterns of oral squamous cell 
carcinoma (OSCC) bone invasion. (A) OSCC 
without bone invasion. (B) Erosive pattern of 
bone invasion with clear interface between 
mandible and OSCC. (C) Invasive pattern of 
bone invasion with irregular front and residual 
bone islands within OSCC.
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to mature osteoclasts (osteoclastogenesis): RANKL and mac-
rophage colony-stimulating factor (M-CSF). Tumor necrosis 
factor (TNF) receptor/TNF-like proteins, including RANKL, its 
receptor RANK, and osteoprotegerin (OPG), regulate osteoclast 
differentiation [27]. RANKL functions a key inducer of bone 
resorption by binding to RANK but OPG acts as a soluble de-
coy receptor [28]. Osteoclastogenesis and activation of bone-
resorbing osteoclasts appears to be the most important factor 
in OSCC bone invasion [29,30]. In OSCC-induced bone inva-
sion, tumor-derived cytokines, including TNF-α, can directly or 
indirectly induce osteoclast formation by stimulating RANKL or 
M-CSF expression [3,31].
Interleukins (ILs), a family of pleiotropic cytokines derived 
from osteoblasts, osteoclasts, and stromal cells, play an im-
portant role in controlling the metabolism of bone [12]. Os-
teoclasts share many regulatory molecules with immune cells, 
thereby several immune cells differentiate as the osteoclasts 
in bone microenvironment [32]. The discovery that cultured 
human peripheral blood leukocytes can absorb bone supports 
the connection between immune system and bone metabo-
lism [33]. IL-1b has been recognized as a primary mediator [34] 
but IL-6, IL-11, and IL-15 as well promote bone resorption 
[35]. Parathyroid hormone-related peptide (PTHrP), another 
key molecule of bone homeostasis, plays a role in prevent-
ing apoptosis of osteoblasts and recruiting osteoclasts, and is 
upregulated in the tissues of OSCC patients [36]. The binding 
of PTHrP to its receptors stimulates osteoclast activity and fa-
cilitates bone destruction [37]. High expression of PTHrP mes-
senger RNA (mRNA) was detected in BHY cells and PTHrP 
mRNA was observed from tumor tissues in 7 of 11 patients 
with the lower alveolar and gingival carcinoma, showing an in-
vasive pattern of bone invasion.
Chemokines, a superfamily of structurally associated cyto-
kines, are classified into four subgroups based on the varia-
tions on a conserved cysteine motif in the protein sequences 
[38]. The CC and CXC are the larger subgroups, whereas CX3C 
and XC are smaller subgroups. Chemokines bind to their cor-
responding G-protein-coupled receptors and induce confor-
mational changes in their transmembrane domain. Some che-
mokines in the bone matrix play a decisive role in osteoclast 
activation [39]. Additionally, chemokines produced by tumor 
cells regulate recruitment and mobilization of osteoclasts [40]. 
CXCL13 and its receptor CXCR5 promoted RANKL expression 
in OSCC cells and prevented bone invasion by OSCC through 
NFATc3 and c-Myc expression [41-43]. CXCL2 was found to 
be involved in bone destruction by expressing RANKL [44].
Growth Factors
Many growth factors influence function of osteoblasts and 
osteoclasts during bone remodeling. In the progression of the 
OSCC, osclast-mediated bone resorption induces secretion of 
growth factors from reservoirs within mineralized bone matrix, 
including transforming growth factor (TGF), epidermal growth 
factor, or connective tissue growth factor, which function as 
local managers of tumor growth and bone destruction [45]. 
Various growth factors advance the local microenvironment 
around tumor cells that express receptors for growth factors, 
promote tumor cell proliferation, and suppress their apoptosis 
[46-48]. TGF-b1 not only induces epithelial-mesenchymal 
transition to increase OSCC invasion capacity but also up-
regulates factors for prolonged osteoclast survival [49]. Recent 
studies have shown that TGF-b1 overexpression promoted 
invasiveness, migration, and angiogenesis of SCC9 cells by 
activating slug/MMP-9 axis [50].
Conclusions
OSCC bone invasion is an extremely coordinated process 
that can described in ‘vicious cycle’ of early, resorption, and 













Fig. 2. Coordinated process of oral squamous cell carcinoma (OSCC) 
bone invasion. In the early stage, proteases degrade the surrounding ex-
tracellular matrix and stimulate OSCC cells to invade the bone tissue. In 
the resorption stage, cytokines regulate osteoclastogenesis and osteoclast-
mediated bone resorption. In the ultimate stage, growth factors released 
from bone matrix promote OSCC growth. The bone invasion deteriorates 
by continuously repeating these stages.
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OSCC cells, osteoblasts, osteoclasts, and bone matrix-derived 
factors (Fig. 2). In the early stage, proteases degrade the ECM 
of the adjacent soft tissues and promote the invasion of OSCC 
into the bone. The next step in bone invasion is the resorption 
stage, where osteoclasts play a major role in absorbing the 
mineral components of the bone. Osteoclast-mediated re-
sorption leads to ultimate stage of bone invasion by secreting 
growth factors from bone matrix and consequently exacerbate 
OSCC bone invasion by promoting the growth of tumor cells.
Previous studies have reported molecular mechanisms asso-
ciated with OSCC invasion, based on OSCC characteristics. Al-
though many researchers are exploring molecular mechanisms 
of OSCC bone invasion, novel targeted markers are still needed 
to quickly predict bone invasion and to treat patients. The use-
ful target molecules that can predict and serve to treat OSCC 
bone invasion will increase early diagnostic and therapeutic 
success and effectively reduce the morbidity and mortality as-
sociated with bone invasion by OSCC.
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